![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ZEB2 |
Gene summary for ZEB2 |
![]() |
Gene information | Species | Human | Gene symbol | ZEB2 | Gene ID | 9839 |
Gene name | zinc finger E-box binding homeobox 2 | |
Gene Alias | HSPC082 | |
Cytomap | 2q22.3 | |
Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | O60315 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
9839 | ZEB2 | CA_HPV_1 | Human | Cervix | CC | 5.83e-03 | 4.03e-01 | 0.0264 |
9839 | ZEB2 | CA_HPV_3 | Human | Cervix | CC | 1.79e-02 | -2.73e-01 | 0.0414 |
9839 | ZEB2 | CCII_1 | Human | Cervix | CC | 3.70e-08 | -5.55e-01 | 0.3249 |
9839 | ZEB2 | Tumor | Human | Cervix | CC | 4.80e-29 | -5.86e-01 | 0.1241 |
9839 | ZEB2 | sample1 | Human | Cervix | CC | 1.94e-04 | -5.13e-01 | 0.0959 |
9839 | ZEB2 | sample3 | Human | Cervix | CC | 1.30e-30 | -5.80e-01 | 0.1387 |
9839 | ZEB2 | H2 | Human | Cervix | HSIL_HPV | 1.04e-26 | -5.74e-01 | 0.0632 |
9839 | ZEB2 | L1 | Human | Cervix | CC | 4.25e-07 | -4.50e-01 | 0.0802 |
9839 | ZEB2 | T1 | Human | Cervix | CC | 4.44e-06 | -4.24e-01 | 0.0918 |
9839 | ZEB2 | T2 | Human | Cervix | CC | 7.15e-03 | -5.43e-01 | 0.0709 |
9839 | ZEB2 | T3 | Human | Cervix | CC | 1.35e-26 | -5.87e-01 | 0.1389 |
9839 | ZEB2 | P9T-E | Human | Esophagus | ESCC | 3.82e-03 | 2.68e-01 | 0.1131 |
9839 | ZEB2 | P11T-E | Human | Esophagus | ESCC | 6.43e-12 | 8.34e-01 | 0.1426 |
9839 | ZEB2 | P12T-E | Human | Esophagus | ESCC | 5.09e-06 | 1.60e-01 | 0.1122 |
9839 | ZEB2 | P19T-E | Human | Esophagus | ESCC | 1.72e-09 | 1.14e+00 | 0.1662 |
9839 | ZEB2 | P24T-E | Human | Esophagus | ESCC | 2.35e-03 | 3.29e-01 | 0.1287 |
9839 | ZEB2 | P32T-E | Human | Esophagus | ESCC | 6.42e-16 | 4.96e-01 | 0.1666 |
9839 | ZEB2 | P37T-E | Human | Esophagus | ESCC | 2.57e-04 | 2.11e-01 | 0.1371 |
9839 | ZEB2 | P44T-E | Human | Esophagus | ESCC | 1.36e-04 | 3.25e-01 | 0.1096 |
9839 | ZEB2 | P49T-E | Human | Esophagus | ESCC | 3.17e-02 | 4.22e-01 | 0.1768 |
Page: 1 2 3 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:009009214 | Thyroid | ATC | regulation of transmembrane receptor protein serine/threonine kinase signaling pathway | 120/6293 | 256/18723 | 6.62e-06 | 6.85e-05 | 120 |
GO:003051113 | Thyroid | ATC | positive regulation of transforming growth factor beta receptor signaling pathway | 19/6293 | 32/18723 | 2.46e-03 | 1.14e-02 | 19 |
GO:190384613 | Thyroid | ATC | positive regulation of cellular response to transforming growth factor beta stimulus | 19/6293 | 32/18723 | 2.46e-03 | 1.14e-02 | 19 |
GO:00901001 | Thyroid | ATC | positive regulation of transmembrane receptor protein serine/threonine kinase signaling pathway | 51/6293 | 114/18723 | 8.62e-03 | 3.28e-02 | 51 |
GO:00330595 | Thyroid | ATC | cellular pigmentation | 26/6293 | 53/18723 | 1.42e-02 | 4.91e-02 | 26 |
Page: 1 2 3 4 5 6 7 8 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ZEB2 | SNV | Missense_Mutation | novel | c.2669N>A | p.Ser890Asn | p.S890N | O60315 | protein_coding | deleterious(0.05) | benign(0.035) | TCGA-3C-AAAU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | zoladex | SD |
ZEB2 | SNV | Missense_Mutation | novel | c.3206C>T | p.Ser1069Leu | p.S1069L | O60315 | protein_coding | deleterious(0) | probably_damaging(0.968) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
ZEB2 | SNV | Missense_Mutation | novel | c.1827G>C | p.Glu609Asp | p.E609D | O60315 | protein_coding | tolerated(0.23) | probably_damaging(0.989) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
ZEB2 | SNV | Missense_Mutation | novel | c.34N>G | p.Cys12Gly | p.C12G | O60315 | protein_coding | deleterious(0.01) | benign(0.007) | TCGA-A2-A04P-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxol | PD |
ZEB2 | SNV | Missense_Mutation | c.3289N>A | p.Glu1097Lys | p.E1097K | O60315 | protein_coding | tolerated(0.17) | probably_damaging(0.972) | TCGA-A8-A092-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | CR | |
ZEB2 | SNV | Missense_Mutation | c.3280N>A | p.Glu1094Lys | p.E1094K | O60315 | protein_coding | deleterious(0.02) | benign(0.444) | TCGA-A8-A09G-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
ZEB2 | SNV | Missense_Mutation | c.270G>T | p.Glu90Asp | p.E90D | O60315 | protein_coding | tolerated(0.91) | benign(0) | TCGA-AR-A250-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
ZEB2 | SNV | Missense_Mutation | c.1204N>C | p.Val402Leu | p.V402L | O60315 | protein_coding | tolerated(0.39) | benign(0) | TCGA-BH-A0AV-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR | |
ZEB2 | SNV | Missense_Mutation | c.3547N>A | p.Glu1183Lys | p.E1183K | O60315 | protein_coding | tolerated_low_confidence(0.1) | benign(0.039) | TCGA-BH-A0B3-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | |
ZEB2 | SNV | Missense_Mutation | rs730881174 | c.905N>A | p.Arg302Gln | p.R302Q | O60315 | protein_coding | deleterious(0) | probably_damaging(0.979) | TCGA-BH-A0HI-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |